We have collected information about Drug Delivery Company Acquisitions for you. Follow the links to find out details on Drug Delivery Company Acquisitions.
https://www.drugdeliverybusiness.com/category/mergers-acquisitions/
Dec 12, 2019 · 3M (NYSE:MMM) announced today that it entered into an agreement to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for approximately $650 million. St. Paul, Minn.-based 3M will retain its transdermal drug delivery components business, according to …
https://drug-dev.com/neurelis-announces-acquisition-of-leading-drug-delivery-technology-company/
Neurelis, Inc. recently announced the acquisition of Aegis Therapeutics, a San Diego-based drug delivery technology company. Aegis Therapeutics’ proprietary portfolio includes Intravail, ProTek, and Hydrogel, three non-invasive drug delivery and stabilization technologies applicable to a wide-range of molecules including therapeutic proteins, peptides, non-peptide macromolecules, and small ...
https://www.biospace.com/news/mergers-and-acquisitions/
Apr 07, 2020 · Sharp Fluidics® acquires neoClose® Laparoscopic and Robotic Port Closure Technology. 4/7/2020. Sharp Fluidics®, LLC, a private medical device company whose innovative Operative Armour® System leads the way in open surgery closure efficiency and safety, announced the acquisition of neoClose®, a laparoscopic and robotic port site closure technology from neoSurgical, LTD.
https://www.outsourcing-pharma.com/Article/2018/03/29/CMOs-CDMOs-give-company-updates-at-DCAT-Week-Acquisitions-expansions-on-all-sides
Mar 29, 2018 · The acquisitions give the company the opportunity to consolidate its headquarters in the US, Colleluori said, as the company will move its center of operations to Morristown, NJ. ... Following the acquisition, the company created a new business unit focused on biologics and specialty drug delivery.
https://www.bd.com/en-us/company/acquisitions
Mergers and acquisitions (M&A) serve as an integral pillar in fulfilling our mission of advancing the world of health by improving medical discovery, diagnostics and the delivery of care.
https://www.drugdeliverybusiness.com/category/mergers-acquisitions/page/4/
Johnson & Johnson (NYSE:JNJ) said today that it accepted a binding offer of more than $2 billion from private equity shop Platinum Equity for its LifeScan blood glucose monitoring business as it moves toward the exit in the diabetes market.
Searching for Drug Delivery Company Acquisitions?
You can just click the links above. The data is collected for you.
